Commerce Bank Acquires 203 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Commerce Bank lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 64,218 shares of the biopharmaceutical company’s stock after acquiring an additional 203 shares during the period. Commerce Bank’s holdings in Gilead Sciences were worth $5,202,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Morgan Stanley lifted its holdings in shares of Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after acquiring an additional 158,794 shares during the period. Norges Bank bought a new position in shares of Gilead Sciences during the 4th quarter worth about $1,301,624,000. Northern Trust Corp lifted its holdings in Gilead Sciences by 3.5% during the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after purchasing an additional 504,475 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Gilead Sciences by 3.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 9,783,195 shares of the biopharmaceutical company’s stock valued at $792,547,000 after purchasing an additional 287,080 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Gilead Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after purchasing an additional 87,482 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GILD. Morgan Stanley cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Mizuho cut their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Barclays cut their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Stock Down 0.7 %

Shares of NASDAQ:GILD opened at $65.68 on Friday. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The company has a 50 day moving average of $68.45 and a 200-day moving average of $74.49. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The stock has a market cap of $81.83 billion, a price-to-earnings ratio of 182.44, a P/E/G ratio of 1.31 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the previous year, the company earned $1.37 EPS. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.69%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.